Pyxis Oncology, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$14M
Cost of Revenue
$2M
R&D
$74M
D&A
$5M
Operating Income
$-84M
EBITDA
$-80M
Interest Income
$650K
Other Income/Expense
$6M
Pretax Income
$-78M
Tax Provision
$1M
Net Income
$-80M
Operating Margin
-609.2%
Net Margin
-574.5%
Effective Tax Rate
-1.8%
Deferred Tax Assets
$3M
Deferred Tax Liabilities
$0
DTA Valuation Allowance
$152M
Tax Credit Carryforwards
$13M
NOL Carryforwards
$96M
ETR (Continuing Operations)
-1.8%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
-0.1%
Operating Lease Cost
$3M
Revenue YoY Variation
-14.2%
Income YoY Variation
5.6%